IRBESARTAN
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (C09CA) — coverage varies; not interchangeable
- Candesartan cilexetil (Atacand): general benefit
- Losartan (Cozaar): general benefit
- Olmesartan medoxomil (Olmetec): general benefit
- Telmisartan (Micardis): general benefit
- Valsartan (Diovan): general benefit, Not a benefit
- Eprosartan (Teveten): general benefit
Irbesartan · DIN 02372347 · 75mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Irbesartan · DIN 02372347
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Marketed since 2025-11-25 · brand IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 75 MG · company Sanis health inc · schedule Prescription
Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85748 · Verify on the e-Formulary ↗ (DIN 02372347)
Source record
DIN 02372347: Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800231; group id 330; item number 0737; lccId None; manufacturer id SAI
Source form: Tab; strength: 75mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02372347
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85748
Interchangeable products
Apo-Irbesartan · DIN 02386968 · $0.2281
Auro-Irbesartan · DIN 02406098 · $0.2281
Avapro · DIN 02237923 · not recorded
Irbesartan · DIN 02385287 · $0.2281
Jamp Irbesartan · DIN 02545225 · $0.2281
Jamp-Irbesartan · DIN 02418193 · $0.2281
M-Irbesartan · DIN 02524813 · $0.2281
Mint-Irbesartan · DIN 02422980 · $0.2281
PMS-Irbesartan · DIN 02317060 · $0.2281
Ran-Irbesartan · DIN 02406810 · $0.2281
Sandoz Irbesartan · DIN 02328461 · $0.2281
Teva-Irbesartan · DIN 02316390 · $0.2281
Shortage status: resolved shortage (ended 2026-02-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02372347
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Irbesartan · DIN 02385287 · 75mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Irbesartan · DIN 02385287
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2012-06-10 · brand IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 75 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87092 · Verify on the e-Formulary ↗ (DIN 02385287)
Source record
DIN 02385287: Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800231; group id 330; item number 0737; lccId None; manufacturer id SIV
Source form: Tab; strength: 75mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385287
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87092
Interchangeable products
Apo-Irbesartan · DIN 02386968 · $0.2281
Auro-Irbesartan · DIN 02406098 · $0.2281
Avapro · DIN 02237923 · not recorded
Irbesartan · DIN 02372347 · $0.2281
Jamp Irbesartan · DIN 02545225 · $0.2281
Jamp-Irbesartan · DIN 02418193 · $0.2281
M-Irbesartan · DIN 02524813 · $0.2281
Mint-Irbesartan · DIN 02422980 · $0.2281
PMS-Irbesartan · DIN 02317060 · $0.2281
Ran-Irbesartan · DIN 02406810 · $0.2281
Sandoz Irbesartan · DIN 02328461 · $0.2281
Teva-Irbesartan · DIN 02316390 · $0.2281
Shortage status: resolved shortage (ended 2024-03-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02385287
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Irbesartan · DIN 02545225 · 75mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Irbesartan · DIN 02545225
Manufacturer: Jamp Pharma Corporation; listing date 2025-04-30
Health Canada: Marketed since 2025-02-04 · brand JAMP IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 75 MG · company Jamp pharma corporation · schedule Prescription
Jamp Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103401 · Verify on the e-Formulary ↗ (DIN 02545225)
Source record
DIN 02545225: Jamp Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800231; group id 330; item number 0737; lccId None; manufacturer id JPC
Source form: Tab; strength: 75mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545225
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103401
Interchangeable products
Apo-Irbesartan · DIN 02386968 · $0.2281
Auro-Irbesartan · DIN 02406098 · $0.2281
Avapro · DIN 02237923 · not recorded
Irbesartan · DIN 02372347 · $0.2281
Irbesartan · DIN 02385287 · $0.2281
Jamp-Irbesartan · DIN 02418193 · $0.2281
M-Irbesartan · DIN 02524813 · $0.2281
Mint-Irbesartan · DIN 02422980 · $0.2281
PMS-Irbesartan · DIN 02317060 · $0.2281
Ran-Irbesartan · DIN 02406810 · $0.2281
Sandoz Irbesartan · DIN 02328461 · $0.2281
Teva-Irbesartan · DIN 02316390 · $0.2281
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02545225
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Irbesartan · DIN 02524813 · 75mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Irbesartan · DIN 02524813
Manufacturer: Mantra Pharma Inc.; listing date 2022-11-30
Health Canada: Marketed since 2026-07-31 · brand M-IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 75 MG · company Mantra pharma inc · schedule Prescription
M-Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101383 · Verify on the e-Formulary ↗ (DIN 02524813)
Source record
DIN 02524813: M-Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800231; group id 330; item number 0737; lccId None; manufacturer id MAT
Source form: Tab; strength: 75mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524813
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101383
Interchangeable products
Apo-Irbesartan · DIN 02386968 · $0.2281
Auro-Irbesartan · DIN 02406098 · $0.2281
Avapro · DIN 02237923 · not recorded
Irbesartan · DIN 02372347 · $0.2281
Irbesartan · DIN 02385287 · $0.2281
Jamp Irbesartan · DIN 02545225 · $0.2281
Jamp-Irbesartan · DIN 02418193 · $0.2281
Mint-Irbesartan · DIN 02422980 · $0.2281
PMS-Irbesartan · DIN 02317060 · $0.2281
Ran-Irbesartan · DIN 02406810 · $0.2281
Sandoz Irbesartan · DIN 02328461 · $0.2281
Teva-Irbesartan · DIN 02316390 · $0.2281
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524813
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Irbesartan · DIN 02422980 · 75mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Irbesartan · DIN 02422980
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2015-05-28
Health Canada: Marketed since 2021-05-17 · brand MINT-IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 75 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90771 · Verify on the e-Formulary ↗ (DIN 02422980)
Source record
DIN 02422980: Mint-Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800231; group id 330; item number 0737; lccId None; manufacturer id MIN
Source form: Tab; strength: 75mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02422980
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90771
Interchangeable products
Apo-Irbesartan · DIN 02386968 · $0.2281
Auro-Irbesartan · DIN 02406098 · $0.2281
Avapro · DIN 02237923 · not recorded
Irbesartan · DIN 02372347 · $0.2281
Irbesartan · DIN 02385287 · $0.2281
Jamp Irbesartan · DIN 02545225 · $0.2281
Jamp-Irbesartan · DIN 02418193 · $0.2281
M-Irbesartan · DIN 02524813 · $0.2281
PMS-Irbesartan · DIN 02317060 · $0.2281
Ran-Irbesartan · DIN 02406810 · $0.2281
Sandoz Irbesartan · DIN 02328461 · $0.2281
Teva-Irbesartan · DIN 02316390 · $0.2281
Shortage status: resolved shortage (ended 2021-05-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02422980
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Irbesartan · DIN 02317060 · 75mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Irbesartan · DIN 02317060
Manufacturer: Pharmascience Inc.; listing date 2011-08-04
Health Canada: Marketed since 2011-03-24 · brand PMS-IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 75 MG · company Pharmascience inc · schedule Prescription
PMS-Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80257 · Verify on the e-Formulary ↗ (DIN 02317060)
Source record
DIN 02317060: PMS-Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800231; group id 330; item number 0737; lccId None; manufacturer id PMS
Source form: Tab; strength: 75mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02317060
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80257
Interchangeable products
Apo-Irbesartan · DIN 02386968 · $0.2281
Auro-Irbesartan · DIN 02406098 · $0.2281
Avapro · DIN 02237923 · not recorded
Irbesartan · DIN 02372347 · $0.2281
Irbesartan · DIN 02385287 · $0.2281
Jamp Irbesartan · DIN 02545225 · $0.2281
Jamp-Irbesartan · DIN 02418193 · $0.2281
M-Irbesartan · DIN 02524813 · $0.2281
Mint-Irbesartan · DIN 02422980 · $0.2281
Ran-Irbesartan · DIN 02406810 · $0.2281
Sandoz Irbesartan · DIN 02328461 · $0.2281
Teva-Irbesartan · DIN 02316390 · $0.2281
Shortage status: resolved shortage (ended 2024-12-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02317060
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Irbesartan · DIN 02406810 · 75mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Irbesartan · DIN 02406810
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2013-11-28
Health Canada: Marketed since 2026-06-30 · brand SPC-IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 75 MG · company Sun pharma canada inc · schedule Prescription
Ran-Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89149 · Verify on the e-Formulary ↗ (DIN 02406810)
Source record
DIN 02406810: Ran-Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800231; group id 330; item number 0737; lccId None; manufacturer id RAN
Source form: Tab; strength: 75mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02406810
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89149
Interchangeable products
Apo-Irbesartan · DIN 02386968 · $0.2281
Auro-Irbesartan · DIN 02406098 · $0.2281
Avapro · DIN 02237923 · not recorded
Irbesartan · DIN 02372347 · $0.2281
Irbesartan · DIN 02385287 · $0.2281
Jamp Irbesartan · DIN 02545225 · $0.2281
Jamp-Irbesartan · DIN 02418193 · $0.2281
M-Irbesartan · DIN 02524813 · $0.2281
Mint-Irbesartan · DIN 02422980 · $0.2281
PMS-Irbesartan · DIN 02317060 · $0.2281
Sandoz Irbesartan · DIN 02328461 · $0.2281
Teva-Irbesartan · DIN 02316390 · $0.2281
Shortage status: resolved shortage (ended 2025-08-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02406810
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Irbesartan · DIN 02328461 · 75mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Irbesartan · DIN 02328461
Manufacturer: Sandoz Canada Inc.; listing date 2011-08-04
Health Canada: Marketed since 2011-03-21 · brand SANDOZ IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 75 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81399 · Verify on the e-Formulary ↗ (DIN 02328461)
Source record
DIN 02328461: Sandoz Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800231; group id 330; item number 0737; lccId None; manufacturer id SDZ
Source form: Tab; strength: 75mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02328461
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81399
Interchangeable products
Apo-Irbesartan · DIN 02386968 · $0.2281
Auro-Irbesartan · DIN 02406098 · $0.2281
Avapro · DIN 02237923 · not recorded
Irbesartan · DIN 02372347 · $0.2281
Irbesartan · DIN 02385287 · $0.2281
Jamp Irbesartan · DIN 02545225 · $0.2281
Jamp-Irbesartan · DIN 02418193 · $0.2281
M-Irbesartan · DIN 02524813 · $0.2281
Mint-Irbesartan · DIN 02422980 · $0.2281
PMS-Irbesartan · DIN 02317060 · $0.2281
Ran-Irbesartan · DIN 02406810 · $0.2281
Teva-Irbesartan · DIN 02316390 · $0.2281
Shortage status: resolved shortage (ended 2025-05-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02328461
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Avapro · DIN 02237924 · 150mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists AVAPRO (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Avapro · DIN 02237924
Manufacturer: Sanofi Aventis Pharma; listing date 1999-04-15
Health Canada: Marketed since 2007-05-14 · brand AVAPRO · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 150 MG · company Sanofi-aventis canada inc · schedule Prescription
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61289 · Verify on the e-Formulary ↗ (DIN 02237924)
Source record
DIN 02237924: Avapro
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800232; group id 330; item number 0738; lccId None; manufacturer id SAV
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.3200; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237924
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61289
Interchangeable products
Apo-Irbesartan · DIN 02386976 · $0.2281
Auro-Irbesartan · DIN 02406101 · $0.2281
Co Irbesartan · DIN 02328089 · $0.2281
Irbesartan · DIN 02372371 · $0.2281
Irbesartan · DIN 02385295 · $0.2281
Jamp Irbesartan · DIN 02545233 · $0.2281
Jamp-Irbesartan · DIN 02418207 · $0.2281
M-Irbesartan · DIN 02524821 · $0.2281
Mint-Irbesartan · DIN 02422999 · $0.2281
PMS-Irbesartan · DIN 02317079 · $0.2281
Ran-Irbesartan · DIN 02406829 · $0.2281
Sandoz Irbesartan · DIN 02328488 · $0.2281
Teva-Irbesartan · DIN 02316404 · $0.2281
Shortage status: resolved shortage (ended 2022-06-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02237924
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Irbesartan · DIN 02372371 · 150mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Irbesartan · DIN 02372371
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Marketed since 2024-07-04 · brand IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 150 MG · company Sanis health inc · schedule Prescription
Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85751 · Verify on the e-Formulary ↗ (DIN 02372371)
Source record
DIN 02372371: Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800232; group id 330; item number 0738; lccId None; manufacturer id SAI
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02372371
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85751
Interchangeable products
Apo-Irbesartan · DIN 02386976 · $0.2281
Auro-Irbesartan · DIN 02406101 · $0.2281
Avapro · DIN 02237924 · $0.2281
Co Irbesartan · DIN 02328089 · $0.2281
Irbesartan · DIN 02385295 · $0.2281
Jamp Irbesartan · DIN 02545233 · $0.2281
Jamp-Irbesartan · DIN 02418207 · $0.2281
M-Irbesartan · DIN 02524821 · $0.2281
Mint-Irbesartan · DIN 02422999 · $0.2281
PMS-Irbesartan · DIN 02317079 · $0.2281
Ran-Irbesartan · DIN 02406829 · $0.2281
Sandoz Irbesartan · DIN 02328488 · $0.2281
Teva-Irbesartan · DIN 02316404 · $0.2281
Shortage status: resolved shortage (ended 2025-12-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02372371
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Irbesartan · DIN 02385295 · 150mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Irbesartan · DIN 02385295
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2012-06-10 · brand IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 150 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87093 · Verify on the e-Formulary ↗ (DIN 02385295)
Source record
DIN 02385295: Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800232; group id 330; item number 0738; lccId None; manufacturer id SIV
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385295
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87093
Interchangeable products
Apo-Irbesartan · DIN 02386976 · $0.2281
Auro-Irbesartan · DIN 02406101 · $0.2281
Avapro · DIN 02237924 · $0.2281
Co Irbesartan · DIN 02328089 · $0.2281
Irbesartan · DIN 02372371 · $0.2281
Jamp Irbesartan · DIN 02545233 · $0.2281
Jamp-Irbesartan · DIN 02418207 · $0.2281
M-Irbesartan · DIN 02524821 · $0.2281
Mint-Irbesartan · DIN 02422999 · $0.2281
PMS-Irbesartan · DIN 02317079 · $0.2281
Ran-Irbesartan · DIN 02406829 · $0.2281
Sandoz Irbesartan · DIN 02328488 · $0.2281
Teva-Irbesartan · DIN 02316404 · $0.2281
Shortage status: resolved shortage (ended 2025-05-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02385295
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Irbesartan · DIN 02545233 · 150mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Irbesartan · DIN 02545233
Manufacturer: Jamp Pharma Corporation; listing date 2025-03-31
Health Canada: Marketed since 2025-02-04 · brand JAMP IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 150 MG · company Jamp pharma corporation · schedule Prescription
Jamp Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103402 · Verify on the e-Formulary ↗ (DIN 02545233)
Source record
DIN 02545233: Jamp Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800232; group id 330; item number 0738; lccId None; manufacturer id JPC
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545233
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103402
Interchangeable products
Apo-Irbesartan · DIN 02386976 · $0.2281
Auro-Irbesartan · DIN 02406101 · $0.2281
Avapro · DIN 02237924 · $0.2281
Co Irbesartan · DIN 02328089 · $0.2281
Irbesartan · DIN 02372371 · $0.2281
Irbesartan · DIN 02385295 · $0.2281
Jamp-Irbesartan · DIN 02418207 · $0.2281
M-Irbesartan · DIN 02524821 · $0.2281
Mint-Irbesartan · DIN 02422999 · $0.2281
PMS-Irbesartan · DIN 02317079 · $0.2281
Ran-Irbesartan · DIN 02406829 · $0.2281
Sandoz Irbesartan · DIN 02328488 · $0.2281
Teva-Irbesartan · DIN 02316404 · $0.2281
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02545233
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Irbesartan · DIN 02524821 · 150mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Irbesartan · DIN 02524821
Manufacturer: Mantra Pharma Inc.; listing date 2022-11-30
Health Canada: Marketed since 2026-07-31 · brand M-IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 150 MG · company Mantra pharma inc · schedule Prescription
M-Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101384 · Verify on the e-Formulary ↗ (DIN 02524821)
Source record
DIN 02524821: M-Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800232; group id 330; item number 0738; lccId None; manufacturer id MAT
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524821
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101384
Interchangeable products
Apo-Irbesartan · DIN 02386976 · $0.2281
Auro-Irbesartan · DIN 02406101 · $0.2281
Avapro · DIN 02237924 · $0.2281
Co Irbesartan · DIN 02328089 · $0.2281
Irbesartan · DIN 02372371 · $0.2281
Irbesartan · DIN 02385295 · $0.2281
Jamp Irbesartan · DIN 02545233 · $0.2281
Jamp-Irbesartan · DIN 02418207 · $0.2281
Mint-Irbesartan · DIN 02422999 · $0.2281
PMS-Irbesartan · DIN 02317079 · $0.2281
Ran-Irbesartan · DIN 02406829 · $0.2281
Sandoz Irbesartan · DIN 02328488 · $0.2281
Teva-Irbesartan · DIN 02316404 · $0.2281
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524821
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Irbesartan · DIN 02422999 · 150mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Irbesartan · DIN 02422999
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2015-05-28
Health Canada: Marketed since 2021-04-28 · brand MINT-IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 150 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90772 · Verify on the e-Formulary ↗ (DIN 02422999)
Source record
DIN 02422999: Mint-Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800232; group id 330; item number 0738; lccId None; manufacturer id MIN
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02422999
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90772
Interchangeable products
Apo-Irbesartan · DIN 02386976 · $0.2281
Auro-Irbesartan · DIN 02406101 · $0.2281
Avapro · DIN 02237924 · $0.2281
Co Irbesartan · DIN 02328089 · $0.2281
Irbesartan · DIN 02372371 · $0.2281
Irbesartan · DIN 02385295 · $0.2281
Jamp Irbesartan · DIN 02545233 · $0.2281
Jamp-Irbesartan · DIN 02418207 · $0.2281
M-Irbesartan · DIN 02524821 · $0.2281
PMS-Irbesartan · DIN 02317079 · $0.2281
Ran-Irbesartan · DIN 02406829 · $0.2281
Sandoz Irbesartan · DIN 02328488 · $0.2281
Teva-Irbesartan · DIN 02316404 · $0.2281
Shortage status: resolved shortage (ended 2021-05-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02422999
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Irbesartan · DIN 02317079 · 150mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Irbesartan · DIN 02317079
Manufacturer: Pharmascience Inc.; listing date 2011-08-04
Health Canada: Marketed since 2011-03-24 · brand PMS-IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 150 MG · company Pharmascience inc · schedule Prescription
PMS-Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80258 · Verify on the e-Formulary ↗ (DIN 02317079)
Source record
DIN 02317079: PMS-Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800232; group id 330; item number 0738; lccId None; manufacturer id PMS
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02317079
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80258
Interchangeable products
Apo-Irbesartan · DIN 02386976 · $0.2281
Auro-Irbesartan · DIN 02406101 · $0.2281
Avapro · DIN 02237924 · $0.2281
Co Irbesartan · DIN 02328089 · $0.2281
Irbesartan · DIN 02372371 · $0.2281
Irbesartan · DIN 02385295 · $0.2281
Jamp Irbesartan · DIN 02545233 · $0.2281
Jamp-Irbesartan · DIN 02418207 · $0.2281
M-Irbesartan · DIN 02524821 · $0.2281
Mint-Irbesartan · DIN 02422999 · $0.2281
Ran-Irbesartan · DIN 02406829 · $0.2281
Sandoz Irbesartan · DIN 02328488 · $0.2281
Teva-Irbesartan · DIN 02316404 · $0.2281
Shortage status: resolved shortage (ended 2021-06-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02317079
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Irbesartan · DIN 02406829 · 150mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Irbesartan · DIN 02406829
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2013-11-28
Health Canada: Marketed since 2026-06-30 · brand SPC-IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 150 MG · company Sun pharma canada inc · schedule Prescription
Ran-Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89150 · Verify on the e-Formulary ↗ (DIN 02406829)
Source record
DIN 02406829: Ran-Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800232; group id 330; item number 0738; lccId None; manufacturer id RAN
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02406829
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89150
Interchangeable products
Apo-Irbesartan · DIN 02386976 · $0.2281
Auro-Irbesartan · DIN 02406101 · $0.2281
Avapro · DIN 02237924 · $0.2281
Co Irbesartan · DIN 02328089 · $0.2281
Irbesartan · DIN 02372371 · $0.2281
Irbesartan · DIN 02385295 · $0.2281
Jamp Irbesartan · DIN 02545233 · $0.2281
Jamp-Irbesartan · DIN 02418207 · $0.2281
M-Irbesartan · DIN 02524821 · $0.2281
Mint-Irbesartan · DIN 02422999 · $0.2281
PMS-Irbesartan · DIN 02317079 · $0.2281
Sandoz Irbesartan · DIN 02328488 · $0.2281
Teva-Irbesartan · DIN 02316404 · $0.2281
Shortage status: resolved shortage (ended 2025-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02406829
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Irbesartan · DIN 02328488 · 150mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Irbesartan · DIN 02328488
Manufacturer: Sandoz Canada Inc.; listing date 2011-08-04
Health Canada: Marketed since 2011-03-21 · brand SANDOZ IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 150 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81400 · Verify on the e-Formulary ↗ (DIN 02328488)
Source record
DIN 02328488: Sandoz Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800232; group id 330; item number 0738; lccId None; manufacturer id SDZ
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02328488
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81400
Interchangeable products
Apo-Irbesartan · DIN 02386976 · $0.2281
Auro-Irbesartan · DIN 02406101 · $0.2281
Avapro · DIN 02237924 · $0.2281
Co Irbesartan · DIN 02328089 · $0.2281
Irbesartan · DIN 02372371 · $0.2281
Irbesartan · DIN 02385295 · $0.2281
Jamp Irbesartan · DIN 02545233 · $0.2281
Jamp-Irbesartan · DIN 02418207 · $0.2281
M-Irbesartan · DIN 02524821 · $0.2281
Mint-Irbesartan · DIN 02422999 · $0.2281
PMS-Irbesartan · DIN 02317079 · $0.2281
Ran-Irbesartan · DIN 02406829 · $0.2281
Teva-Irbesartan · DIN 02316404 · $0.2281
Shortage status: resolved shortage (ended 2025-06-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02328488
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Avapro · DIN 02237925 · 300mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists AVAPRO (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Avapro · DIN 02237925
Manufacturer: Sanofi Aventis Pharma; listing date 1999-04-15
Health Canada: Marketed since 2007-05-03 · brand AVAPRO · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 300 MG · company Sanofi-aventis canada inc · schedule Prescription
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61290 · Verify on the e-Formulary ↗ (DIN 02237925)
Source record
DIN 02237925: Avapro
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800233; group id 330; item number 0739; lccId None; manufacturer id SAV
Source form: Tab; strength: 300mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.3200; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237925
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61290
Interchangeable products
Apo-Irbesartan · DIN 02386984 · $0.2281
Auro-Irbesartan · DIN 02406128 · $0.2281
Co Irbesartan · DIN 02328100 · $0.2281
Irbesartan · DIN 02372398 · $0.2281
Irbesartan · DIN 02385309 · $0.2281
Jamp Irbesartan · DIN 02545241 · $0.2281
Jamp-Irbesartan · DIN 02418215 · $0.2281
M-Irbesartan · DIN 02524848 · $0.2281
Mint-Irbesartan · DIN 02423006 · $0.2281
PMS-Irbesartan · DIN 02317087 · $0.2281
Ran-Irbesartan · DIN 02406837 · $0.2281
Sandoz Irbesartan · DIN 02328496 · $0.2281
Teva-Irbesartan · DIN 02316412 · $0.2281
Shortage status: resolved shortage (ended 2022-09-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02237925
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Irbesartan · DIN 02372398 · 300mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Irbesartan · DIN 02372398
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Marketed since 2025-11-25 · brand IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 300 MG · company Sanis health inc · schedule Prescription
Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85752 · Verify on the e-Formulary ↗ (DIN 02372398)
Source record
DIN 02372398: Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800233; group id 330; item number 0739; lccId None; manufacturer id SAI
Source form: Tab; strength: 300mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02372398
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85752
Interchangeable products
Apo-Irbesartan · DIN 02386984 · $0.2281
Auro-Irbesartan · DIN 02406128 · $0.2281
Avapro · DIN 02237925 · $0.2281
Co Irbesartan · DIN 02328100 · $0.2281
Irbesartan · DIN 02385309 · $0.2281
Jamp Irbesartan · DIN 02545241 · $0.2281
Jamp-Irbesartan · DIN 02418215 · $0.2281
M-Irbesartan · DIN 02524848 · $0.2281
Mint-Irbesartan · DIN 02423006 · $0.2281
PMS-Irbesartan · DIN 02317087 · $0.2281
Ran-Irbesartan · DIN 02406837 · $0.2281
Sandoz Irbesartan · DIN 02328496 · $0.2281
Teva-Irbesartan · DIN 02316412 · $0.2281
Shortage status: resolved shortage (ended 2025-12-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02372398
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Irbesartan · DIN 02385309 · 300mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Irbesartan · DIN 02385309
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2012-06-10 · brand IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 300 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87094 · Verify on the e-Formulary ↗ (DIN 02385309)
Source record
DIN 02385309: Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800233; group id 330; item number 0739; lccId None; manufacturer id SIV
Source form: Tab; strength: 300mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385309
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87094
Interchangeable products
Apo-Irbesartan · DIN 02386984 · $0.2281
Auro-Irbesartan · DIN 02406128 · $0.2281
Avapro · DIN 02237925 · $0.2281
Co Irbesartan · DIN 02328100 · $0.2281
Irbesartan · DIN 02372398 · $0.2281
Jamp Irbesartan · DIN 02545241 · $0.2281
Jamp-Irbesartan · DIN 02418215 · $0.2281
M-Irbesartan · DIN 02524848 · $0.2281
Mint-Irbesartan · DIN 02423006 · $0.2281
PMS-Irbesartan · DIN 02317087 · $0.2281
Ran-Irbesartan · DIN 02406837 · $0.2281
Sandoz Irbesartan · DIN 02328496 · $0.2281
Teva-Irbesartan · DIN 02316412 · $0.2281
Shortage status: resolved shortage (ended 2020-11-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02385309
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Irbesartan · DIN 02545241 · 300mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Irbesartan · DIN 02545241
Manufacturer: Jamp Pharma Corporation; listing date 2025-03-31
Health Canada: Marketed since 2025-02-04 · brand JAMP IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 300 MG · company Jamp pharma corporation · schedule Prescription
Jamp Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103403 · Verify on the e-Formulary ↗ (DIN 02545241)
Source record
DIN 02545241: Jamp Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800233; group id 330; item number 0739; lccId None; manufacturer id JPC
Source form: Tab; strength: 300mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545241
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103403
Interchangeable products
Apo-Irbesartan · DIN 02386984 · $0.2281
Auro-Irbesartan · DIN 02406128 · $0.2281
Avapro · DIN 02237925 · $0.2281
Co Irbesartan · DIN 02328100 · $0.2281
Irbesartan · DIN 02372398 · $0.2281
Irbesartan · DIN 02385309 · $0.2281
Jamp-Irbesartan · DIN 02418215 · $0.2281
M-Irbesartan · DIN 02524848 · $0.2281
Mint-Irbesartan · DIN 02423006 · $0.2281
PMS-Irbesartan · DIN 02317087 · $0.2281
Ran-Irbesartan · DIN 02406837 · $0.2281
Sandoz Irbesartan · DIN 02328496 · $0.2281
Teva-Irbesartan · DIN 02316412 · $0.2281
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02545241
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Irbesartan · DIN 02524848 · 300mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Irbesartan · DIN 02524848
Manufacturer: Mantra Pharma Inc.; listing date 2022-11-30
Health Canada: Marketed since 2026-07-31 · brand M-IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 300 MG · company Mantra pharma inc · schedule Prescription
M-Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101385 · Verify on the e-Formulary ↗ (DIN 02524848)
Source record
DIN 02524848: M-Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800233; group id 330; item number 0739; lccId None; manufacturer id MAT
Source form: Tab; strength: 300mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524848
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101385
Interchangeable products
Apo-Irbesartan · DIN 02386984 · $0.2281
Auro-Irbesartan · DIN 02406128 · $0.2281
Avapro · DIN 02237925 · $0.2281
Co Irbesartan · DIN 02328100 · $0.2281
Irbesartan · DIN 02372398 · $0.2281
Irbesartan · DIN 02385309 · $0.2281
Jamp Irbesartan · DIN 02545241 · $0.2281
Jamp-Irbesartan · DIN 02418215 · $0.2281
Mint-Irbesartan · DIN 02423006 · $0.2281
PMS-Irbesartan · DIN 02317087 · $0.2281
Ran-Irbesartan · DIN 02406837 · $0.2281
Sandoz Irbesartan · DIN 02328496 · $0.2281
Teva-Irbesartan · DIN 02316412 · $0.2281
Shortage status: resolved shortage (ended 2024-09-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524848
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Irbesartan · DIN 02423006 · 300mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Irbesartan · DIN 02423006
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2015-05-28
Health Canada: Marketed since 2021-04-28 · brand MINT-IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 300 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90773 · Verify on the e-Formulary ↗ (DIN 02423006)
Source record
DIN 02423006: Mint-Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800233; group id 330; item number 0739; lccId None; manufacturer id MIN
Source form: Tab; strength: 300mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423006
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90773
Interchangeable products
Apo-Irbesartan · DIN 02386984 · $0.2281
Auro-Irbesartan · DIN 02406128 · $0.2281
Avapro · DIN 02237925 · $0.2281
Co Irbesartan · DIN 02328100 · $0.2281
Irbesartan · DIN 02372398 · $0.2281
Irbesartan · DIN 02385309 · $0.2281
Jamp Irbesartan · DIN 02545241 · $0.2281
Jamp-Irbesartan · DIN 02418215 · $0.2281
M-Irbesartan · DIN 02524848 · $0.2281
PMS-Irbesartan · DIN 02317087 · $0.2281
Ran-Irbesartan · DIN 02406837 · $0.2281
Sandoz Irbesartan · DIN 02328496 · $0.2281
Teva-Irbesartan · DIN 02316412 · $0.2281
Shortage status: resolved shortage (ended 2026-01-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02423006
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Irbesartan · DIN 02317087 · 300mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Irbesartan · DIN 02317087
Manufacturer: Pharmascience Inc.; listing date 2011-08-04
Health Canada: Marketed since 2011-03-24 · brand PMS-IRBESARTAN · ATC C09CA04 IRBESARTAN · form Tablet · route Oral · ingredients IRBESARTAN 300 MG · company Pharmascience inc · schedule Prescription
PMS-Irbesartan: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2281 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80259 · Verify on the e-Formulary ↗ (DIN 02317087)
Source record
DIN 02317087: PMS-Irbesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800233; group id 330; item number 0739; lccId None; manufacturer id PMS
Source form: Tab; strength: 300mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2281; ministry $0.2281
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02317087
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80259
Interchangeable products
Apo-Irbesartan · DIN 02386984 · $0.2281
Auro-Irbesartan · DIN 02406128 · $0.2281
Avapro · DIN 02237925 · $0.2281
Co Irbesartan · DIN 02328100 · $0.2281
Irbesartan · DIN 02372398 · $0.2281
Irbesartan · DIN 02385309 · $0.2281
Jamp Irbesartan · DIN 02545241 · $0.2281
Jamp-Irbesartan · DIN 02418215 · $0.2281
M-Irbesartan · DIN 02524848 · $0.2281
Mint-Irbesartan · DIN 02423006 · $0.2281
Ran-Irbesartan · DIN 02406837 · $0.2281
Sandoz Irbesartan · DIN 02328496 · $0.2281
Teva-Irbesartan · DIN 02316412 · $0.2281
Shortage status: anticipated shortage (last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02317087
Shortage record checked 2026-09-13T08:10:21.292534+00:00